Skip to main content
TipRanks
Go Ultimate75% OFF

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) AI Stock Analysis

2 Followers
HK:8189

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

(HKEX:8189)

Select Model
Rating:40Underperform
Price Target:HKD 0.10â–¼(-5.00% Downside)
Action:reiterated
Date:11/17/26

The score is primarily constrained by persistently negative profitability and cash flow, a sharply weakened equity base, and high leverage. Technical weakness and an unhelpful earnings-based valuation further reduce the score; the only notable offset is recent revenue growth and deeply oversold technical readings.

Positive Factors
Revenue reboundThe sharp 2025 revenue rebound indicates that demand or commercial activity recovered materially, restoring scale to the pharmaceutical and medical-products business. If retained, this larger revenue base could improve operating leverage and provide more capacity to support product development and distribution.
Negative Factors
Persistent unprofitabilityVery low gross margin and continuing operating and net losses show that revenue recovery has not yet translated into a sustainable earnings model. Widening net losses reduce internal funding capacity and leave the business more exposed if margins do not improve over the next several quarters.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) vs. iShares MSCI Hong Kong ETF (EWH)

-80%-60%-40%-20%0%20%HK:8189-73.68%EWH+9.24%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 213.39M
Dividend Yield
―
Average Volume (3M)
961.77K
Price to Earnings (P/E)
-8.7
Beta (1Y)
0.28
Revenue Growth
53.32%
EPS Growth
-122.35%
Country
Hong Kong
Employees
273
Sector
Basic Materials
Sector Strength
61
Industry
Agricultural Inputs

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Tianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based in Tianjin, People's Republic of China, is a diversified enterprise primarily involved in the research, development, manufacturing, and distribution of biological compound...

How the Company Makes Money

The company primarily makes money by selling its pharmaceutical and/or medical-related products to customers (e.g., hospitals, pharmacies, distributors, or other healthcare institutions), generating revenue from product sales. Additional revenue stre...

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Financial Statement Overview

Summary

Financial performance is severely weak: profitability remains negative, shareholders’ equity has declined substantially, debt is high relative to equity, and operating cash flow has been negative in five of six years. Revenue growth provides a limited positive offset.

Income Statement

24Negative

Balance Sheet

16Very Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue881.37M509.43M385.48M398.00M403.73M476.38M
Gross Profit70.68M34.75M16.97M21.37M14.82M45.60M
EBITDA-8.26M-14.08M-22.11M4.79M-2.26M-29.86M
Net Income-109.96M-88.47M-27.80M-20.16M-27.45M-42.26M
Balance Sheet
Total Assets443.76M264.96M332.53M303.28M337.20M347.60M
Cash, Cash Equivalents and Short-Term Investments65.29M29.22M25.40M5.93M9.55M29.78M
Total Debt108.79M109.79M159.92M83.56M102.61M90.34M
Total Liabilities414.97M262.22M304.09M238.70M256.05M237.24M
Stockholders Equity22.43M12.23M22.15M49.95M70.11M100.78M
Cash Flow
Free Cash Flow106.08M-62.84M-28.83M-15.62M-21.62M-40.38M
Operating Cash Flow119.16M-54.58M-26.27M-13.15M-12.82M-6.68M
Investing Cash Flow34.56M31.36M-37.24M-467.44K-12.93M-8.51M
Financing Cash Flow-75.01M27.03M82.95M12.73M6.17M28.10M

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Technical Analysis

Technical Analysis SentimentNegative
Last Price0.10

Price Trends

50DMA0.20Negative
100DMA0.19Negative
200DMA0.23Negative

Market Momentum

MACD-0.03Negative
RSI17.17Positive
STOCH13.26Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8189, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.20, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 17.17 is Positive, neither overbought nor oversold. The STOCH value of 13.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8189.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

HK:8189 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
HK:2198HK:219860NeutralHKD 3.56B3.9513.63%4.94%0.90%16.54%
HK:0301HK:030143NeutralHKD 3.70B-199.03-8.09%―3.15%50.74%
HK:8189HK:818940UnderperformHKD 213.39M-8.66-634.56%―53.32%-122.35%
HK:2112HK:211237UnderperformHKD 28.50M-0.1314.68%―-45.65%29.13%

* Basic Materials Sector Average

Performance Comparison

0%200%400%600%800%HK:8189HK:2112HK:2198HK:0301HK:0660HK:2565Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:8189 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:8189Tianjin TEDA Biomedical Engineering Co. Ltd. Class H0.10-0.28-73.33%
HK:2112Grace Life-tech Holdings Limited0.02-0.04-69.35%
HK:2198China Sanjiang Fine Chemicals Co., Ltd.3.040.238.32%
HK:0301SANVO Fine Chemicals Group Limited7.886.38425.00%
HK:0660Wai Chun Bio-Technology Ltd.0.390.1559.18%
HK:2565PegBio Co., Ltd. Class H2.85-61.75-95.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026